Drug namePrazosin
DescriptionA selective adrenergic alpha-1 antagonist used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud`s syndrome, prostatic hypertrophy, and urinary retention. [PubChem]
DrugBankPrimary Accession Number: DB00457
DIN01910302
TypeApproved, Small Molecule
IndicationFor treatment of hypertension and chronic heart failure.
Mechanism of ActionPrazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
AbsorptionWell-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%).
ToxicityNot available
Protein Binding97%
Interactions
RXListhttp://www.rxlist.com/cgi/generic3/prazosin.htm
KEGGdrug: Not available / compound: C07368
PubChemcompound: 4893 / substance: 9572
PharmGKBPA451093
Metabolizing Enzymes
NameGeneEntrezIDUniprotSNP
Target
NameGeneEntrezIDSwissprotSNP
Alpha-1A adrenergic receptorADRA1A148ADA1A_HUMANrs56318220 rs56233953 rs59765666 rs1048101 rs56394436 rs7833704 rs3730287 rs3730247 rs2229126 rs2229125 rs2229124 rs1496121 rs1383914 rs1048102
Alpha-1B adrenergic receptorADRA1B147ADA1B_HUMANrs34322837 rs8192450 rs8192448 rs3730284 rs3729604 rs2229181
Alpha-1D adrenergic receptorADRA1D146ADA1D_HUMANrs55915202 rs55926349 rs35105284 rs3803964
FilesDB00457.mol | DB00457_584.pdf | pdb_2603738925473-0.pdb | sdf_42432014996-0.sdf |
Smilesisomeric:
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
canonical:
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1

© 2010-2020 All rights reserved. King Abdullah University of Science and Technology, All rights reserved